A RANDOMIZED PHASE 3 TRIAL OF VINORELBINE, DACTINOMYCIN, AND CYCLOPHOSPHAMIDE (VINO-AC) PLUS MAINTENANCE CHEMOTHERAPY WITH VINORELBINE AND ORAL CYCLOPHOSPHAMIDE (VINO-CPO) VS VINCRISTINE, DACTINOMYCIN AND CYCLOPHOSPHAMIDE (VAC) PLUS VINO-CPO MAINTENANCE IN PATIENTS WITH HIGH RISK RHABDOMYOSARCOMA (HR-RMS)

Registry ID

ARST2031

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

CHILDRENS ONCOLOGY GROUP

Start date

2021-11-30

Last update

2021-10-05

Conditions

• RHABDOMYOSARCOMA

Related clinical trials

• A PROSPECTIVE PHASE 3 STUDY OF PATIENTS WITH NEWLY DIAGNOSED VERY LOW-RISK AND LOW-RISK FUSION NEGATIVE RHABDOMYOSARCOMA
• A RANDOMIZED PHASE 3 STUDY OF VINCRISTINE, DACTINOMYCIN, CYCLOPHOSPHAMIDE (VAC) ALTERNATING WITH VINCRISTINE AND IRINOTECAN (VI) VERSUS VAC/VI PLUS TEMSIROLIMUS (TORI, TORISEL, NSC# 683864, IND# 122782) IN PATIENTS WITH INTERMEDIATE RISK (IR) RHABDOMYOSARCOMA (RMS)

View on source registry